Ariosa Diagnostics scored expanded Medicaid and private insurance coverage for its noninvasive prenatal test, building momentum after its recent deal with diagnostics heavyweight Roche and giving the company a boost in a fiercely competitive market.
The Sunnyvale, CA-based company's Xpert Norovirus test runs on Cepheid's GeneXpert System and can differentiate between GI and GII norovirus genogroups in as little as one hour, Chief Medical and Technology Officer David Persing said in a statement.
POPULAR COMMENT THREADS
Roche snatched up AvanSci Bio's tissue dissection technology for the analysis of tumors, diversifying its product offerings and continuing its molecular diagnostics push.
Santa Ana, CA-based MP Biomedicals has nabbed FDA approval for the first supplemental test designed to better identify blood donors that have tested positive for human T cell lymphotropic virus.
In vitro diagnostics outfit BacterioScan closed an oversubscribed Series A financing round to support development of its next-generation, rapid diagnostic test for urinary tract infection.
Roche got a green light from U.S. regulatory authorities to expand the use of two tests from its cobas assay line used to detect serious viral infections like HIV, hepatitis B and C and West Nile.
Ortho-Clinical Diagnostics rolled out Astute Medical's test for acute kidney injury in U.S. hospitals, chalking up a milestone in the companies' push to commercialize the product.
Epigenomics won marketing approval in China for its next-generation colorectal cancer test, moving the company forward on its path toward global commercialization for the product and helping it compete in an increasingly competitive playing field.
From Our Sister Sites
AbbVie won an expected FDA approval for its next-generation treatment for hepatitis C, kicking off a race with Gilead Sciences for dominance in a blockbuster field.
Despite loud objections from its advisers, the FDA granted an accelerated approval to AstraZeneca's ovarian cancer treatment, clearing an oral therapy the U.K. drugmaker believes will bring in blockbuster sales.